Clinical trial · Interventional
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend the time period until further growth of the tumor more than gemcitabine alone.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Metastasis | Bladder Neoplasm | PROBABILISTIC | 0.70 |
| Transitional Cell Carcinoma | Transitional Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Placebo | Other | — | UNRESOLVED |
| Vinflunine | Drug | Vinflunine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- vinflunine and gemcitabine
- description
- solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
- interventionNames
- Drug: Vinflunine
- Drug: Gemcitabine
- type
- PLACEBO_COMPARATOR
- label
- placebo and gemcitabine
- description
- solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
- interventionNames
- Drug: Gemcitabine
- Other: Placebo
Primary outcomes (1)
- measure
- Median Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria in Participants With Advanced Transitional Cell Carcinoma (TCC) of the Urothelium
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic * Ineligible for cisplatin-based therapy because of at least one of the following two medical conditions: * Calculated creatinine clearance ≤60 mL/min: OR * New York Heart Association Classification Stage III-IV Congestive Heart Failure * Measurable disease documented by imaging with at least one uni-dimensional lesion * Adequate performance status (ECOG 0, 1, or 2) * Men and women ≥18 years of age Exclusion Criteria: * Patients in whom radiation or surgery is indicated * Current neuropathy ≥ CTCAE grade 3 * Prior radiation to ≥ 30% of bone marrow * Inadequate renal function: serum creatinine clearance ≤ 20 mL/min * Prior allergy to any vinca alkaloid
References
Publications (0)
Data not yet available